Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 71 от 222

Набира участници

The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis

Primary Angle-Closure Glaucoma

Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.

Начало: 01.10.2025 Край: 30.09.2027 Възраст: от 50 г.

China Zhongnan Hospital NCT07539675

Набира участници Фаза 2

Study of COYA 302 for the Treatment of ALS

Amyotrophic Lateral Sclerosis (ALS)

The ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS). COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. It is comprised of low dose interleukin-2 (LD IL-2) and DRL\_AB (a biosimilar candidate for abatacept). Participants will be randomly assigned to receive one of 2 regimens of COYA 302 or placebo (an inactive substance) for 24-weeks in the double-blind (DB) period. Those who complete this part of the study may be eligible to receive one of the two regimens of COYA 302 for an additional 24 weeks in a blinded active extension phase (EXT). The study will assess changes in disease progression using established ALS clinical outcome measures, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament (NfL), maximal inspiratory pressure (MIP), slow vital capacity (SVC), and neurological assessments. Additional objectives include evaluation of biomarkers and safety through routine clinical assessments and adverse event monitoring.

Начало: 01.10.2025 Край: 01.07.2027 Възраст: 18–80 г.

Canada, United States Coya Therapeutics NCT07161999

Набира участници

Visual Arts Interventions With Older Adults

Feasibility Study

The present study investigates the feasibility, acceptability, and preliminary effects of a novel visual arts-based intervention in an older adult population. In a randomized controlled design, two arts-based interventions will be evaluated with a group of 50 participants.

Начало: 01.10.2025 Край: 30.09.2026 Възраст: 55–85 г.

United States Northeastern University NCT06645652

Набира участници Фаза 1

Safety of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy Volunteer

Healthy Volunteers Non Diabetic Hyperglycemia

Volunteers were divided into 2 groups: mulberry leaf extract capsule (DNJ 12mg) group and placebo group. They took the sample 3 times/day for 8 weeks. Complete blood count, Blood urea nitrogen (BUN), Creatinine, Aspartate transaminase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Fasting plasma glucose, HbA1c, and adverse effects were evaluated before and after 4 and 8 weeks.

Начало: 01.10.2025 Край: 24.09.2026 Възраст: от 18 г.

Thailand Chulalongkorn University NCT07532135

Набира участници

The Hyalex MTP Study

Hallux Valgus Hallux Limitus Hallux Rigidus

The HYALEX SLALOM MTP Hemiarthroplasty System consists of a synthetic implant designed to replace the distal metatarsal surface of the great toe for treatment of arthritis . The system is composed of the HYALEX MTP Implant and instrumentation. The implant consists of the HYALEX Cartilage material bonded to a titanium backing.

Начало: 01.10.2025 Край: 31.12.2027 Възраст: 21–75 г.

Poland Hyalex Orthopaedics, Inc. NCT07538141

Набира участници Фаза 2

A Randomized Controlled Trial on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy in Subjects With Moderate to Severe Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy (DPN)

This clinical trial aims to evaluate the efficacy and safety of human umbilical cord mesenchymal stem cell (hUC-MSC) injection in the treatment of adults with moderate to severe diabetic peripheral neuropathy. Researchers will compare hUC-MSCs injection combined with conventional therapy (experimental group) to conventional therapy alone (control group) to see if hUC-MSCs work to treat diabetic peripheral neuropathy. The experimental group will receive three injections of hUC-MSCs (on Day 0, Day 7, and Day 28) while continuing conventional therapy, whereas the control group will receive conventional therapy only. Participants will undergo regular follow-ups for checkups and tests over a 24-week period. The primary endpoint of the study is the change in the Toronto Clinical Scoring System (TCSS) score at Week 24. Safety assessments will be conducted throughout the entire study period, with extended follow-up until Week 104 to evaluate long-term safety.

Начало: 01.10.2025 Край: 30.08.2028 Възраст: 18–80 г.

China Min Long NCT07183761

Набира участници

The Multicentre Selective Lymphadenectomy Trial - 3

Cutaneous Melanoma, Stage III

The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either selective index lymph node resection (ILN) (identified at baseline as the largest affected lymph node) or the standard of care therapeutic lymph node dissection (TLND). The secondary aims are to assess if patients who are managed without TLND will have a reduction in surgical complications (less wound problems \& lymphoedema), an improved quality of life, at a lower healthcare utilisation.

Начало: 01.10.2025 Край: 01.08.2040 Възраст: от 18 г. Друго

Australia, Canada, Italy +2 Melanoma Institute Australia NCT07049276

Набира участници Фаза 1

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

Myeloproliferative Neoplasms

This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.

Начало: 01.10.2025 Край: 14.12.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Germany +2 Incyte Corporation NCT07008118

Набира участници Фаза 1

Serum Collection Study for Assay Development

Pneumococcal Disease, Invasive Pneumococcal Disease

The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation

Начало: 01.10.2025 Край: 01.06.2026 Възраст: 18–69 г. Диагностика

Australia GPN Vaccines NCT07205289

Набира участници

Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes

Type 2 Diabetes Osteoporosis Diabetic Neuropathies Fall Prevention +1

The DIACTIVE study is a randomized controlled trial with a 5- year follow-up designed to evaluate the impact of comprehensive screening and multicomponent interventions on fall prevention, bone health, nerve function and cardiovascular outcomes in people with diabetes aged 65 years and older on the short and longer term. Diabetes significantly increases risks of falls, fractures, and cardiovascular disease, yet these areas remain underexplored in clinical research. This trial addresses these gaps with a novel, multidimensional approach. Participants undergo extensive baseline assessments, including fall risk stratification, bone mineral density measurements via DXA scans, neuropathy evaluations, and cardiovascular profiling. Based on these evaluations, participants are allocated to risk-based intervention arms. The study's centerpiece is the RYMA and ADL exercise program, a tailored cognitive-motor training regimen integrating strength, balance, and executive function exercises with music-based coordination tasks. Pharmacological treatments for osteoporosis and optimization of cardiovascular risk profiles (e.g., SGLT2 inhibitors, GLP-1 agonists) are also incorporated. Primary outcomes focus on reducing fall rates by at least 30%, improving bone density, mitigating fracture risks, enhancing nerve function, and lowering cardiovascular event rates. Secondary endpoints explore mechanisms underlying fall reduction, quality of life improvements, and adherence to interventions. Advanced methodologies such as gait analysis, seismocardiography, and magnetic resonance imaging (MRI) provide detailed insights into the intervention's effects. Follow-ups at 26 weeks, 52 weeks, 2 years, and 5 years ensure long-term efficacy evaluation. This trial is conducted at Steno Diabetes Center North and involves interdisciplinary collaboration. By addressing key complications of diabetes through integrated care, the study aims to improve patient outcomes and inform future healthcare strategies for older people with diabetes.

Начало: 01.10.2025 Край: 31.12.2027 Възраст: от 65 г.

Denmark Aalborg University Hospital NCT06745544

Набира участници Фаза 1

A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma

Metastatic Melanoma

This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.

Начало: 01.10.2025 Край: 01.07.2027 Възраст: от 18 г. Лечение

Australia Adze Biotechnology Australia Pty Ltd NCT07086105

Набира участници Фаза 1/2

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

Advanced Tumors

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.

Начало: 01.10.2025 Край: 30.06.2031 Възраст: от 18 г. Лечение

Australia, Israel ModeX Therapeutics, An OPKO Health Company NCT07110584

Набира участници Фаза 1

A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

Locoregionally Recurrent Hormone-receptor Positive Breast Cancer Metastatic Hormone Receptor Positive Breast Cancer

A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.

Начало: 01.10.2025 Край: 01.06.2033 Възраст: от 18 г. Лечение

Australia, United States Radionetics Oncology NCT07121244

Набира участници Фаза 2

Role of Estrogen on Skeletal Outcomes in FHA

Bone Strength Bone Density FHA (Functional Hypothalamic Amenorrhea)

The purpose of this study is to assess whether the natural form of estrogen (17-beta estradiol) given as a patch so that it is absorbed through your skin, is better at improving bone strength over 1 year than natural estrogen (17-beta estradiol) taken by mouth, or a synthetic form oestrogen (ethinyl estradiol) given as a patch that also provides birth control. Participants will: 1. Take estrogen for 1 year either (i) in its natural form as a patch twice a week (and progesterone by mouth for 12 days of each month), or (ii) in its natural form as a pill daily (and progesterone by mouth for 12 days of each month), or (iii) in a synthetic form as a birth control patch weekly for 3 weeks with 1 week off the patch. You will not be able to choose which form of estrogen you will receive as this will be assigned to you based on a pre-existing randomization sequence (like the flip of a coin) 2. Take provided calcium and vitamin D supplements 3. Attend 4 study visits over 12 months with two at the beginning and then every 6 months that include: * History and Physical Exams * Lab Work * Imaging studies * Questionnaires * Dietary recalls

Начало: 01.10.2025 Край: 31.05.2030 Възраст: 14–30 г.

United States University of Virginia NCT07010146

Набира участници

Effect of Manual Chest Wall Vibration on Respiratory Function and Chest Tube Duration After Thoracic Surgery

Thoracic Diseases

This study was conducted to determine the effects of a manual vibration technique applied to the chest wall on the duration of chest tube placement, secretion clearance, and hemodynamic parameters in patients with chest tubes.

Начало: 01.10.2025 Край: 01.05.2026 Възраст: от 18 г.

Turkey (Türkiye) Saglik Bilimleri Universitesi NCT07549555

Набира участници Фаза 2

Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder

Adjustment Disorder Adjustment Disorder With Anxious Mood Cancer Cancer Cachexia +7

This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustment disorder. Study details Participants in this study will be randomly allocated by chance (similar to flipping a coin) to one of three groups: a 25mg NPX-5 dose group, a 10 mg NPX-5 dose group or a 1mg NPX-5 dose group. Participants will be allocated a dose that will be administered during their psilocybin-assisted psychotherapy (PAP) dosing session. The PAP dosing session will run approximately 8 hours, with NPX-5 administered at Day 14 (dosing day). At Week 10, non-responders that continue to meet the study eligibility criteria may commence an additional PAP cycle (at 25 mg NPX-5). A maximum of 2 PAP cycles may be administered. Long term follow up will comprise of a study visit at 3 months post Week 10 (of the final cycle) to assess safety and tolerability of NPX-5. It is hoped that this research will develop important scientific knowledge that could contribute to the development of a potential new treatment for anxiety and depression after adjusting to an acutely stressful event such as a cancer diagnosis.

Начало: 01.10.2025 Край: 30.07.2027 Възраст: 18–80 г. Лечение

Australia Psyence Australia Pty Ltd NCT07072728

Набира участници Фаза 2

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Pulmonary Arterial Hypertension (PAH) Pulmonary Hypertension, Interstitial Lung Disease

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval/authorization.

Начало: 01.10.2025 Край: 01.03.2029 Възраст: от 18 г. Лечение

Australia, Canada, France +4 AllRock Bio, Inc. NCT07175038

Набира участници Фаза 3

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops tiny open ulcers).

Начало: 01.10.2025 Край: 13.01.2032 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +23 Janssen Research & Development, LLC NCT07196748

Набира участници

Prostate Adaptive Radiation Therapy

Prostatic Neoplasms

Prostate ART is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients. Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced. Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2. Part 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for prostate cancer patients.

Начало: 01.10.2025 Край: 31.10.2031 Възраст: от 18 г. Лечение

Australia Royal North Shore Hospital NCT06547398

Набира участници

Suicide Prevention After Community Care Discharge

Suicide Prevention

The study is of high importance to Veterans' health because it will study a suicide prevention intervention in a Veteran population that is at high risk of suicide but has not been a specific focus of the Veteran Affairs' (VA's) suicide prevention efforts. Specifically, a growing number of Veterans are now receiving acute mental health treatment in VA-purchased settings (commonly referred to as Community Care). While these Veterans are at high risk of suicide after discharge, very little is known about how to prevent suicide in these Veterans. This study will directly address this problem by looking at whether a promising suicide prevention strategy called the VA Brief Intervention and Contact Program (VA BIC) can decrease the risk of suicide in Veterans after they are discharged from a non-VA mental health treatment setting. The proposed research is highly pertinent to the VA's top clinical priority-to prevent suicide in Veterans.

Начало: 01.10.2025 Край: 30.09.2028 Възраст: от 18 г.

United States VA Office of Research and Development NCT06596044

1 … 69 70 71 72 73 … 222